Trinity Biotech plc
NASDAQ:TRIBMedical - Diagnostics & Research
-$0.51 today
- Market cap
- $117.96M
- Beta
- 1.00
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.27
Volume 0.00M
Average 1.34M
TRIB Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Trinity Biotech plcNASDAQ: TRIB
Financing Cash Flow · Q4 FY2025 · quarter ended Dec 2025
Financing cash flow growth accelerates
Q4 FY2025 financing cash flow of $6.15M rose 240.8% year over year, ahead of the -57.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 360.5% from the prior quarter.
Context
- Financing cash flow amounted to 27.5% of revenue in FY2025, down 19.3 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +240.8% holds above the trailing-twelve-month pace of -57.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 12.05M USD
- Year-over-year change
- -58.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.05M | -58.2% |
| FY2024 | 2024-12-31 | 28.81M | +279.6% |
| FY2023 | 2023-12-31 | (16.04M) | -30.2% |
| FY2022 | 2022-12-31 | (12.32M) | -104.7% |
| FY2021 | 2021-12-31 | (6.02M) | — |
Financing Cash Flow vs competitors
How TRIB compares with its peers on the latest reported figures
No competitor Financing Cash Flow figures are available to compare.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 875K | (41.01M) | (24.02M) | (31.79M) | (37.38M) |
| Depreciation & Amortization | 2.74M | 2.33M | 1.78M | 1.87M | 2.68M |
| Deferred Income Tax | (167K) | (192K) | (59K) | 486K | 199K |
| Stock-Based Compensation | 1.1M | 1.76M | 2.07M | 1.32M | 324K |
| Change in Working Capital | (172K) | (1.66M) | (2.69M) | 6.19M | 7.03M |
| Accounts Receivables | 6.24M | (966K) | 1.05M | (2.37M) | 4.92M |
| Inventory | (4.41M) | (877K) | (971K) | (1.74M) | 90K |
| Accounts Payables | (7.59M) | 181K | (2.77M) | 8.19M | 0 |
| Other Working Capital | 5.59M | 7.57M | (478K) | 10.3M | 2.02M |
| Other Non-Cash Items | 8.86M | 37.85M | 11.37M | 17.74M | 21.21M |
| Operating Cash Flow | 13.24M | (921K) | (11.56M) | (4.19M) | (5.93M) |
| Capital Expenditures | (8.69M) | (5.98M) | (803K) | (10.06M) | (6.22M) |
| Acquisitions (Net) | 0 | 0 | 28.16M | (12.9M) | 0 |
| Purchases of Investments | 0 | 0 | (700K) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (6.88M) | (4.88M) | (1.9M) | (9.66M) | (6.14M) |
| Investing Cash Flow | (8.69M) | (5.98M) | 24.76M | (22.97M) | (6.22M) |
| Debt Repayment | (2.94M) | (27.04M) | (7.37M) | 27.67M | 11.81M |
| Common Stock Issued | 0 | 25.34M | 0 | 7.39M | 547K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.08M) | (10.61M) | (8.67M) | (6.25M) | (308K) |
| Financing Cash Flow | (6.02M) | (12.32M) | (16.04M) | 28.81M | 12.05M |
| Effect of Forex Changes | 55K | (112K) | (44K) | (175K) | 71K |
| Net Change in Cash | (1.42M) | (19.33M) | (2.89M) | 1.48M | (29K) |
| Free Cash Flow | 4.55M | (6.9M) | (12.36M) | (14.26M) | (12.15M) |
Trinity Biotech plc
NASDAQ:TRIB
Intrinsic Alpha fair value
Locked
Current Price
$5.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.